Nature Communications (Nov 2020)

Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

  • Jared S. Mackenzie,
  • Dirk A. Lamprecht,
  • Rukaya Asmal,
  • John H. Adamson,
  • Khushboo Borah,
  • Dany J. V. Beste,
  • Bei Shi Lee,
  • Kevin Pethe,
  • Simon Rousseau,
  • Inna Krieger,
  • James C. Sacchettini,
  • Joel N. Glasgow,
  • Adrie J. C. Steyn

DOI
https://doi.org/10.1038/s41467-020-19959-4
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 16

Abstract

Read online

Bedaquiline (BDQ) is a known tuberculosis treatment, but the precise mechanism of cell death is unclear. Here, the authors explore the metabolic profiles of M. tuberculosis upon BDQ treatment and find reliance on glycolysis and synergistic cell death when oxidative phosphorylation is also targeted.